Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M

Natera, Inc.

2021-FY EPS reported -$5.21 revenue$625,486,000

Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.
Q4 net loss $140.6M ($1.48/share) vs $76.4M loss ($0.89/share) in Q4 2020; FY 2021 net loss $471.7M ($5.21/share).
Processed ~438,800 tests in Q4 (+48.7% YoY); full year ~1,570,000 tests processed.
FY 2022 guidance: revenue $770M-$790M; gross margin ~46%-48%; SG&A $560M-$590M; R&D $340M-$360M; net cash consumption $370M-$400M.
Received CMS coverage for Signatera pan-cancer monitoring; presented positive data from Trifecta and CIRCULATE-Japan studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.